CHP
AIMT

Cable Hill Partners’s Aimmune Therapeutics AIMT Stock Holding History

Cable Hill Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,112
Closed -$25K – 802
2019
Q1 		$25K Buy
1,112
+500
+82% +$11.8K 0.01% 344
2018
Q4 		$15K Buy
612
+500
+446% +$12.9K 0.01% 391
2018
Q3 		$3K Sell
112
-20
-15% -$566 ﹤0.01% 687
2018
Q2 		$4K Hold
132
– – ﹤0.01% 751
2018
Q1 		$4K Sell
132
-216
-62% -$7.6K ﹤0.01% 743
2017
Q4 		$13K Hold
348
– – 0.01% 519
2017
Q3 		$9K Sell
348
-8
-2% -$172 ﹤0.01% 621
2017
Q2 		$7K Sell
356
-1
-0.3% -$19 ﹤0.01% 497
2017
Q1 		$8K Buy
357
+5
+1% +$103 ﹤0.01% 461
2016
Q4 		$7K Hold
352
– – ﹤0.01% 493
2016
Q3 		$6K Sell
352
-38
-10% -$513 ﹤0.01% 541
2016
Q2 		$5K Hold
390
– – ﹤0.01% 520
2016
Q1 		$6K Buy
+390
New +$6.08K ﹤0.01% 461

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cable Hill Partners's AIMT Position: Q2 2019 in Review

Cable Hill Partners sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 1,112 shares — an estimated $25K sold.

Cable Hill Partners first reported a position in AIMT in Q1 2016 and held it in 13 quarters. The position peaked at $25K in Q1 2019. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • Cable Hill Partners reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 1,112 Aimmune Therapeutics shares in Q2 2019, an estimated $25K.
  • Cable Hill Partners first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 13 quarters.
  • Cable Hill Partners's Aimmune Therapeutics position peaked at $25K in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.